Equities

Nykode Therapeutics ASA

Nykode Therapeutics ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)5.10
  • Today's Change-0.39 / -7.10%
  • Shares traded1.11m
  • 1 Year change-81.79%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments162206228
Total Receivables, Net1.074.3326
Total Inventory------
Prepaid expenses2.011.151.30
Other current assets, total0.650.540.47
Total current assets166212256
Property, plant & equipment, net119.539.17
Goodwill, net------
Intangibles, net0.070.030.03
Long term investments------
Note receivable - long term3200.48
Other long term assets------
Total assets208221266
LIABILITIES
Accounts payable1.332.312.75
Accrued expenses4.215.104.06
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.461.151.35
Other current liabilities, total143023
Total current liabilities213931
Total long term debt4.274.375.82
Total debt5.735.517.17
Deferred income tax122129
Minority interest------
Other liabilities, total0.000.034.91
Total liabilities376472
SHAREHOLDERS EQUITY
Common stock0.370.340.33
Additional paid-in capital1298382
Retained earnings (accumulated deficit)4576115
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.05)(3.05)(3.12)
Total equity171157194
Total liabilities & shareholders' equity208221266
Total common shares outstanding327295290
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.